Publikationen



2017

Hehlmann R.; Lauseker M.; Saussele S.; Pfirrmann M.; Krause S.; Kolb H.J.; Neubauer A.; Hossfeld D.K.; Nerl C.; Gratwohl A.; Baerlocher G.M.; Heim D.; Bruemmendorf T.H.; Fabarius A.; Haferlach C.; Schlegelberger B.; Mueller M.C.; Jeromin S.; Proetel U.; Kohlbrenner K.; Voskanyan A.; Rinaldetti S.; Seifarth W.; Spiess B.; Balleisen L.; Goebeler M.C.; Haenel M.; Ho A.; Dengler J.; Falge C.; Kanz L.; Kremers S.; Burchert A.; Kneba M.; Stegelmann F.; Koehne C.A.; Lindemann H.W.; Waller C.F.; Pfreundschuh M.; Spiekermann K.; Berdel W.E.; Mueller L.; Edinger M.; Mayer J.; Beelen D.W.; Bentz M.; Link H.; Hertenstein B.; Fuchs R.; Wernli M.; Schlegel F.; Schlag R.; de Wit M.; Truemper L.; Hebart H.; Hahn M.; Thomalla J.; Scheid C.; Schafhausen P.; Verbeek W.; Eckart M.J.; Gassmann W.; Pezzutto A.; Schenk M.; Brossart P.; Geer T.; Bildat S.; Schaefer E.; Hochhaus A.; Hasford J.
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Leukemia : (2017-08-14)



Dang N.H.; Ogura M.; Castaigne S.; Fayad L.E.; Jerkeman M.; Radford J.; Pezzutto A.; Bondarenko I.; Stewart D.A.; Shnaidman M.; Sullivan S.; Vandendries E.; Tobinai K.; Ramchandren R.; Hamlin P.A.; Giné E.; Ando K.
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
British Journal of Haematology : (2017-07-05)



Rieger K.; Guenther U.; Erben U.; Kühl A.; Loddenkemper C.; Pezzutto A.; Siegmund B.; Bojarski C.
Confocal endomicroscopy in diagnosis of intestinal chronic graft-versus-host disease
Hematological Oncology : (2017-05-25)



2016

Berenstein R.; Nogai A.; Waechter M.; Blau O.; Kuehnel A.; Schmidt-Hieber M.; Kunitz A.; Pezzutto A.; Doerken B.; Blau I.W.
Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223
Molecular Carcinogenesis 55 (12): 1927-1939 (2016-12)



Gaetjen M.; Brand F.; Grau M.; Gerlach K.; Kettritz R.; Westermann J.; Anagnostopoulos I.; Lenz P.; Lenz G.; Hoepken U.E.; Rehm A.
Splenic marginal zone granulocytes acquire an accentuated neutrophil B cell-helper phenotype in chronic lymphocytic leukemia.
Cancer Research 76 (18): 5253-5265 (2016-09)



Nguyen-Hoai T.; Pham-Duc M.; Gries M.; Doerken B.; Pezzutto A.; Westermann J.
CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model
Cancer Gene Therapy 23 (6): 162-167 (2016-06)



Korfel A.; Schlegel U.; Herrlinger U.; Dreyling M.; Schmidt C.; von Baumgarten L.; Pezzutto A.; Grobosch T.; Kebir S.; Thiel E.; Martus P.; Kiewe P.
Phase II Trial of temsirolimus for relapsed/refractory primary CNS lymphoma
Journal of Clinical Oncology 34 (15): 1757-1763 (2016-05-20)



Ferrero S.; Pastore A.; Scholz C.W.; Forstpointner R.; Pezzutto A.; Bergmann L.; Truemper L.; Finke J.; Keller U.; Ghione P.; Passera R.; Hiddemann W.; Weigert O.; Unterhalt M.; Dreyling M.
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial
Leukemia 30 (4): 984-987 (2016-04)



2015

Mensen A.; Oh Y.; Becker S.C.; Hemmati P.G.; Jehn C.; Westermann J.; Szyska M.; Goeldner H.; Doerken B.; Scheibenbogen C.; Arnold R.; Na I.K.
Apoptosis-susceptibility prolongs the lack of memory B cells in acute leukemic patients after allogeneic hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation 21 (11): 1895–1906 (2015-11)



Schneider T.; Floercken A.; Singh A.; Tuerkmen S.; Burmeister T.; Anagnostopoulos I.; Pezzutto A.; Doerken B.; Westermann J.
Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia
Annals of Hematology 94 (8): 1337-1345 (2015-08)



Oden F.; Marino S.F.; Brand J.; Scheu S.; Kriegel C.; Olal D.; Takvorian A.; Westermann J.; Yilmaz B.; Hinz M.; Daumke O.; Hoepken U.E.; Mueller G.; Lipp M.
Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma
Molecular Oncology 9 (7): 1348-1358 (2015-08)



Saussele S.; Krauss M.P.; Hehlmann R.; Lauseker M.; Proetel U.; Kalmanti L.; Hanfstein B.; Fabarius A.; Kraemer D.; Berdel W.E.; Bentz M.; Staib P.; de Wit M.; Wernli M.; Zettl F.; Hebart H.F.; Hahn M.; Heymanns J.; Schmidt-Wolf I.; Schmitz N.; Eckart M.J.; Gassmann W.; Bartholomaeus A.; Pezzutto A.; Oppliger Leibundgut E.; Heim D.; Krause S.W.; Burchert A.; Hofmann W.K.; Hasford J.; Hochhaus A.; Pfirrmann M.; Mueller M.C.
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML-Study IV
Blood 126 (1): 42-49 (2015-07-02)



Lerch K.; Meyer A.H.; Stroux A.; Hirt C.; Keller U.; Viardot A.; Marks R.; Schreiber S.; Pezzutto A.; Scholz C.W.
Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis
Annals of Hematology 94 (6): 981-988 (2015-06)



Berenstein R.; Blau I.W.; Suckert N.; Baldus C.; Pezzutto A.; Doerken B.; Blau O.
Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia
Journal of Experimental & Clinical Cancer Research 34 (1): 55 (2015-05-22)



Floercken A.; Grau M.; Wolf A.; Weilemann A.; Kopp J.; Doerken B.; Blankenstein T.; Pezzutto A.; Lenz P.; Lenz G.; Westermann J.
Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-{kappa}B
International Journal of Cancer 136 (8): 1814-1826 (2015-04-15)



Berenstein R.; Blau O.; Nogai A.; Waechter M.; Slonova E.; Schmidt-Hieber M.; Kunitz A.; Pezzutto A.; Doerken B.; Blau I.W.
Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region
BMC Cancer 15 (1): 68 (2015-02-18)



2014

Heinig K.; Gaetjen M.; Grau M.; Stache V.; Anagnostopoulos I.; Gerlach K.; Niesner R.A.; Cseresnyes Z.; Hauser A.E.; Lenz P.; Hehlgans T.; Brink R.; Westermann J.; Doerken B.; Lipp M.; Lenz G.; Rehm A.; Hoepken U.E.
Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B cell activation and proliferation
Cancer Discovery 4: 1448-1465 (2014-12)



Mensen A.; Joehrens K.; Anagnostopoulos I.; Demski S.; Oey M.; Stroux A.; Hemmati P.; Westermann J.; Blau O.; Wittenbecher F.; Movassaghi K.; Szyska M.; Thomas S.; Doerken B.; Scheibenbogen C.; Arnold R.; Na I.K.
Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT
Blood 124 (6): 963-972 (2014-08-07)



Ceko M.; Milenkovic N.; Le Coutre P.; Westermann J.; Lewin G.R.
Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans
Pain 155 (7): 1222-1228 (2014-07)



Jehn C.F.; Boening L.; Kroening H.; Pezzutto A.; Lueftner D.
Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer
European Journal of Cancer 50 (7): 1269-1275 (2014-05)



Singh A.; Schabath R.; Ratei R.; Stroux A.; Klemke C.D.; Nebe T.; Floercken A.; van Lessen A.; Anagnostopoulos I.; Doerken B.; Ludwig W.D.; Pezzutto A.; Westermann J.
Peripheral blood sCD3(-) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma
Hematological Oncology 32 (1): 16-21 (2014-03)



Keilholz U.; Pezzutto A.; Budach V.; Eggert A.
Long-term structured follow-up is essential after curative cancer treatment
Deutsches Aerzteblatt International 111 (1-2): 1-2 (2014-01-06)



Meyer A.H.; Stroux A.; Lerch K.; Eucker J.; Eitle J.; Hohloch K.; Andrzejak M.; Possinger K.; Doerken B.; Pezzutto A.; Scholz C.W.
Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma
Annals of Oncology 25 (1): 210-215 (2014-01)



2013

Weikert S.; Kempkensteffen C.; Busch J.; Johannsen M.; Gruenwald V.; Zimmermann K.; Floercken A.; Westermann J.; Weinkauf L.; Miller K.; Keilholz U.
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
World Journal of Urology 31 (4): 805-809 (2013-08)



Pohla H.; Buchner A.; Stadlbauer B.; Frankenberger B.; Stevanovic S.; Walter S.; Frank R.; Schwachula T.; Olek S.; Kopp J.; Willimsky G.; Stief C.G.; Hofstetter A.; Pezzutto A.; Blankenstein T.; Oberneder R.; Schendel D.J.
High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination
Molecular Medicine 18: 1499-1508 (2013-02-08)



Scholz C.W.; Pinto A.; Linkesch W.; Linden O.; Viardot A.; Keller U.; Hess G.; Lastoria S.; Lerch K.; Frigeri F.; Arcamone M.; Stroux A.; Frericks B.; Pott C.; Pezzutto A.
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial
Journal of Clinical Oncology 31 (3): 308-313 (2013-01-20)



2012

Jehn C.F.; Flath B.; Strux A.; Krebs M.; Possinger K.; Pezzutto A.; Lueftner D.
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer
Breast Cancer Research and Treatment 136 (3): 789-794 (2012-12)



2011

Waiczies H.; Lepore S.; Janitzek N.; Hagen U.; Seifert F.; Ittermann B.; Purfuerst B.; Pezzutto A.; Paul F.; Niendorf T.; Waiczies S.
Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells
PLoS ONE 6 (7): e21981 (2011-07-19)



Westermann J.; Floercken A.; Willimsky G.; van Lessen A.; Kopp J.; Takvorian A.; Joehrens K.; Lukowsky A.; Schoenemann C.; Sawitzki B.; Pohla H.; Frank R.; Doerken B.; Schendel D.J.; Blankenstein T.; Pezzutto A.
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
Gene Therapy 18 (4): 354-363 (2011-04)



2010

Buchner A.; Pohla H.; Willimsky G.; Frankenberger B.; Frank R.; Baur-Melnyk A.; Siebels M.; Stief C.G.; Hofstetter A.; Kopp J.; Pezzutto A.; Blankenstein T.; Oberneder R.; Schendel D.J.
Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma
Human Gene Therapy 21 (3): 285-297 (2010-03)



2009

Westermann J.; Hecker A.C.; Floercken A.; Doerken B.; Pezzutto A.
Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome
Journal of Immunotherapy 32 (6): 667-675 (2009-07)



2008

Morschhauser F.; Seymour J.F.; Kluin-Nelemans H.C.; Grigg A.; Wolf M.; Pfreundschuh M.; Tilly H.; Raemaekers J.; van't Veer M.B.; Milpied N.; Cartron G.; Pezzutto A.; Spencer A.; Reyes F.; Dreyling M.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Annals of Oncology 19 (2): 247-253 (2008-02)



2007

Westermann J.; Nguyen-Hoai T.; Baldenhofer G.; Hoepken U.E.; Lipp M.; Doerken B.; Pezzutto A.
CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity
Cancer Gene Therapy 14 (6): 523-532 (2007-06)



Westermann J.; Kopp J.; van Lessen A.; Hecker A.C.; Baskaynak G.; le Coutre P.; Doehner K.; Doehner H.; Doerken B.; Pezzutto A.
Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
British Journal of Haematology 137 (4): 297-306 (2007-05)



2006

Subklewe M.; Marquis R.; Choquet S.; Leblond V.; Garnier J.L.; Hetzer R.; Swinnen L.J.; Oertel S.; Papp-Vary M.; Gonzalez-Barca E.; Hepkema B.G.; Schoenemann C.; May J.; Pezzutto A.; Riess H.
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation
Transplantation 82 (8): 1093-1100 (2006-10-27)



Sebelin K.; Schulzki A.; Kloetzel P.M.; Doerken B.; Pezzutto A.; Subklewe M.
Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients
Transplantation 82 (6): 779-787 (2006-09-27)



Salmon D.; Aido-Machado R.; Diehl A.; Leidert M.; Schmetzer O.; de Lima A.P.; Scharfstein J.; Oschkinat H.; Pires J.R.
Solution structure and backbone dynamics of the Trypanosoma cruzi cysteine protease inhibitor chagasin
Journal of Molecular Biology 357 (5): 1511-1521 (2006-04-14)



Westermann J.; Lessen A.; Schlimper C.; Baskaynak G.; Coutre P.; Doerken B.; Pezzutto A.
Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia
British Journal of Haematology 132: 32-35 (2006-01)



2005

Stuehmer T.; Chatterjee M.; Hildebrandt M.; Herrmann P.; Gollasch H.; Gerecke C.; Theurich S.; Cigliano L.; Manz R.A.; Daniel P.T.; Bommert K.; Vassilev L.T.; Bargou R.C.
Non-genotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Blood 106: 3609-3617 (2005-08-04)



Schmetzer O.; Moldenhauer G.; Riesenberg R.; Pires J.R.; Schlag P.M.; Pezzutto A.
Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein
Journal of Immunology 174 (2): 942-952 (2005-01-01)



Frankenberger B.; Pohla H.; Noessner E.; Willimsky G.; Papier B.; Pezzutto A.; Kopp J.; Oberneder R.; Blankenstein T.; Schendel D.J.
Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs
Clinical Cancer Research 11: 1733-1742 (2005-01-01)



Bienert M.; Reisinger I.; Srock S.; Humplik B.I.; Reim C.; Kroessin T.; Avril N.; Pezzutto A.; Munz D.L.
Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience
European Journal of Nuclear Medicine and Molecular Imaging 32: 1225-1233 (2005-01-01)



2004

Westermann J.; Schlimper C.; Richter G.; Mohm J.; Doerken B.; Pezzutto A.
T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia
British Journal of Haematology 125 (2): 213-216 (2004-04-01)



Kim Y.M.; Mapara M.Y.; Down J.D.; Johnson K.W.; Boisgerault F.; Akiyama Y.; Benichou G.; Pelot M.; Zhao G.; Sykes M.
Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning
Blood 103: 732-739 (2004-01-15)



Westermann J.; Nguyen-Hoai T.; Mollweide A.; Richter G.; Schmetzer O.; Kim H.J.; Blankenstein T.; Doerken B.; Pezzutto A.
Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization
Gene Therapy 11 (13): 1048-1056 (2004-01-01)



2003

Rubio M.T.; Kim Y.M.; Sachs T.; Mapara M.; Zhao G.; Sykes M.
Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma
Blood 102: 2300-2307 (2003-09-15)



Schlenk R.F.; Benner A.; Hartmann F.; del Valle F.; Weber C.; Pralle H.; Fischer J.T.; Gunzer U.; Pezzutto A.; Weber W.; Grimminger W.; Preiss J.; Hensel M.; Froehling S.; Doehner K.; Haas R.; Doehner H.
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial
Leukemia 17 (8): 1521-1528 (2003-08-01)



Westermann J.; Koerner I.J.; Kopp J.; Kurz S.; Zenke M.; Doerken B.; Pezzutto A.
Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties
Cancer Immunology Immunotherapy 52 (3): 194-198 (2003-03)



2001

Richter G.; Hayden-Ledbetter M.; Irgang M.; Ledbetter J.A.; Westermann J.; Koerner I.; Daemen K.; Clark E.A.; Aicher A.; Pezzutto A.
Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells
Journal of Biological Chemistry 276 (49): 45686-45693 (2001-01-01)



2000

Nielsen M.B.; Monsurro V.; Migueles S.A.; Wang E.; Perez-Diez A.; Lee K.H.; Kammula U.; Rosenberg S.A.; Marincola F.M.
Status of activation of circulating vaccine-elicited CD8+ T cells
Journal of Immunology 165: 2287-2296 (2000-08-15)



Aicher A.; Hayden-Ledbetter M.; Brady W.A.; Pezzutto A.; Richter G.; Magaletti D.; Buckwalter S.; Ledbetter J.A.; Clark E.A.
Characterization of human inducible costimulator ligand expression and function
Journal of Immunology 164 (9): 4689-4696 (2000-05-01)



Panelli M.C.; Riker A.; Kammula U.; Wang E.; Lee K.H.; Rosenberg S.A.; Marincola F.M.
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases
Journal of Immunology 164: 495-504 (2000-01-01)



1999

Aicher A.; Shu G.L.; Magaletti D.; Mulvania T.; Pezzutto A.; Craxton A.; Clark E.A.
Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells
Journal of Immunology 163: 5786-5795 (1999-12-01)



Daniel P.T.; Scholz C.; Essmann F.; Westermann J.; Pezzutto A.; Doerken B.
CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism
Experimental Hematology 27: 1402-1408 (1999-09-01)



Cayeux S.; Richter G.; Becker C.; Pezzutto A.; Doerken B.; Blankenstein T.
Direct and indirect T cell priming by dendritic cell vaccines
European Journal of Immunology 29: 225-234 (1999-01-01)



1998

Daniel P.T.; Kroidl A.; Kopp J.; Sturm I.; Moldenhauer G.; Doerken B.; Pezzutto A.
Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "Veto" apoptosis of antibody-targeted cytotoxic T cells
Blood 92 (12): 4750-4757 (1998-12-15)



Daniel P.T.; Kroidl A.; Cayeux S.; Scholz C.; Sturm I.; Blankenstein T.; Pezzutto A.; Doerken B.
Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis
Advances in Experimental Medicine and Biology 451: 265-276 (1998-01-01)



Westermann J.; Aicher A.; Qin Z.; Cayeux S.; Daemen K.; Blankenstein T.; Doerken B.; Pezzutto A.
Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation
Gene Therapy 5: 264-271 (1998-01-01)



1997

Aicher A.; Westermann J.; Cayeux S.; Willimsky G.; Daemen K.; Blankenstein T.; Uckert W.; Doerken B.; Pezzutto A.
Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells
Experimental Hematology 25: 39-44 (1997-01-01)



Cayeux S.; Richter G.; Becker C.; Beck C.; Aicher A.; Pezzutto A.; Doerken B.; Blankenstein T.
Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency
European Journal of Immunology 27: 1657-1662 (1997-01-01)